Fig. 5.

Mφ and Gr1⁺ cell depletion during in vivo reprogramming. (A) Representative flow cytometry plots and quantification of F4/80 and CD11b double-positive populations in blood 16 h after liposome (LP) were administered intraperitoneally on day 3 of reprogramming. Mice were randomly selected (n=4). Cells were gated from CD45⁺ cells. (B) Representative H&E and F4/80 immunohistochemistry of the spleen of mice treated with doxycycline and empty or clodronate LP for 7 days. (C) Dysplasia quantification in the pancreas of mice reprogrammed with empty or clodronate LP for 7 days (n=6 for WT, n=10 for empty LP and n=11 for clodronate LP groups). (D) Representative flow cytometry plots and quantification of Ly6C and CD11b, and Ly6G and CD11b populations in blood on day 5 from reprogramming from mice treated with anti-Gr1 or isotype control antibodies. Cells were gated from CD45⁺ cells. (E) Representative H&E, neutrophil elastase (NE) and Gr1 immunohistochemistry in the spleen of partially reprogrammed mice treated with anti-Gr1 or isotype control antibodies for 7 days. (F) Dysplasia quantification in the pancreas of mice reprogrammed for 7 days with either anti-Gr1 or isotype control (n=8 for WT and n=11 for i4F and anti-Gr1 groups). All data are mean±s.d.; *P<0.05, ***P<0.001 evaluated using the unpaired two-tailed Student's t-test. ns, not significant.